Subject Index

Accuracy of χ² approximation 34–35
Actuarial curves 55, see also Kaplan-Meier Adjustment
   for confounding 47–48, 52–53, 155
   for covariates 117, 125, 130, 163, 198
   for heterogeneity in 2 × 2 tables 46–51,
   133–135
   for prognostic factors 69
Agreement and reliability 298–309
   observer agreement 299
   observer reliability 299
Alpha (α) 209, 210, 211, 230–231,
   246–247
Analysis
   initial 193–196
   primary 196–200
   secondary 200–201
Analysis of variance 118, 124–127,
   174–190
   as linear regression with categorical
   covariates 175–181
   components of total variation 123
   degrees of freedom 123, 179
   explained/residual variation 122–123
   F test 124–127, 179
   lack of fit 127
   main effects model 180–181
   mean square 124, 301
   pure error 126–127
R² 124
   repeated measures 160, 185
   repeat observations 126
     on same subject 160
   sum of squares 123, 179, 186–187
     between patients 186
     lack of fit 127
     model 123
     pure error 126–127
     residual 123
     total 123
     within patients 186
   variance estimate 126
     with observer effects 300
     with subject effects 300
     with two-factor interactions 181–183,
     187
   ANOVA tables 118, 122–127, 174, 179,
   186–187
Association 111, 119, 130, 163
Bar graph, see Histogram
Beta (β) 209–211
Binary data 19
   paired 46, 51–53
Binary variable 128
   expected value 129
Binomial coefficient 21
Bonferroni adjustment 202, 206, 241
Case-control study 135, 264, 268–273
comparison of disease rates 264
Categorical measurements 174–175, see also Categories
Categorical variables, see Categorical measurements
Categories grouping 196–197, 204
response variable 196
using indicator variables 175–181, 181–183, 196–197, 276
Caterpillar plot, see Meta-analysis, graphical displays
Censored survival times 56, 59, 60, 149
independence assumption 60
Central limit theorem 81, 82
Chance 16, 17
Chi-squared (χ²) distribution 33, 34, 40, 42–45, 69
link with normal 83–84
mean 42
variance 42
Chi-squared (χ²) test for 2 × 2 tables 28–35, 202
for rectangular tables 35–42, 203
increasing significance 204
Chronic diseases 149
Clinical trials, see also Design of clinical trials
conditional power 252
equivalence 236–237
hazards of small 214–216
intention to treat analysis 227
non-inferiority 237
sequential analysis 230–233
for a single outcome 230–233
for efficacy-toxicity outcomes 244–250
size, see Sample size
stochastic curtailment 250–253
use of orthogonal contrasts 243
Cohort population-based 264
study 263
Column totals 20
Combining 2 × 2 tables 46–51
Combining rows and columns 38, 40–42
Common variance assumption 103, 106–110
Comparable events, set 18, 21
Comparison of survival curves 67–75
adjusting for other factors 69
restricted 70
Comparisons with normal data 100–110
paired 100–103
unpaired 103–106
Confidence intervals 84–87
95% 85, 86
based on t distribution 97–100
definition 84, 85
difference in population means 104–106
in equivalence trials 236–237
information provided by 85, 86
length 85–86
level of confidence 85
mean of normally distributed data 96–98
odds ratio 132
regression coefficients 132, 144, 153
relative risk 153
Confounding factor 47–51, 270
Consistency between data and hypothesis 11, 14–15, 17
with null hypothesis 17, 18
Contingency table 2 × 2 12, 28–35
rectangular 35–42
Continuity correction, see Yates
Controls, see Design of clinical trials
Correlation 118–122, 162
coefficient 119
effect of selection 120
in longitudinal studies 160, 162, 164–165
versus regression 118–122
Covariate 113, 129, 150, 168–169, see also
Explanatory variable
fixed 158
time-dependent 157–159, 265
Cox regression model, see Proportional hazards regression
Critical values χ² distribution 42–45
F-distribution 106, 107–108
normal distribution 83
t distribution 98, 99
Cumulative hazard 157
Cumulative mortality figure 145
Cumulative probability curve, see Probability curve
Cured fraction of patients 59–60

Data
analysis 191–206
cleaning up 193–196
missing 192
quality 191–192
retrospective/prospective collection 192–193, 263–264

Death rate, see also Hazard rate
at time t 150
regression model 150
relation to survival curve 151

Degrees of freedom, see also Analysis of variance
χ² distribution 42
F distribution 106
t distribution 97–98

Delta (δ) 104, 210, 236
clinically relevant difference 210
departure from therapeutic equivalence 236–237
difference in means 104

Design of clinical trials 217–253
active control 236–237
cluster randomized study 238
cross-over trial 238
data collection 218
Data Monitoring Committee 222
early stopping, see sequential designs
efficacy-toxicity 244–250
equivalence, see active control
ethics committee 221
factorial designs 228
group randomized trial 238
group sequential designs 231–233, 244–250
multiple outcomes 239–242, 244
summary response 240, 242
multiple treatment arms 242–244
n-of-1 trial 238
parallel group design 237
questions to be answered 217
randomized versus historical controls 222–227
sequential designs 230–233, 244–250
treatment assignment 218, 219
treatment selection 218
Trial Management Committee 221
trial organization 220–222
trial protocol 221
Trial Steering Committee 221

Deviance 205

Diagnostic test 282–297
false negative error 287
false negative outcome 286
false positive error 287
false positive outcome 286
likelihood ratios 292
of a negative test result 293
of a positive test result 292
post-test probability of disease 288
converting prevalence to 288–292, 293–295
post-test probability of no disease 288
converting prevalence to 288–292, 294–295
predictive value of a negative test outcome 288
predictive value of a positive test outcome 288
pretest probability of disease 288
prevalence 288
sensitivity 286–287
specificity 287
spectrum of study subjects 287–288
true negative outcome 286
ture positive outcome 286
use of binary outcomes 284

Discordant pairs 53

Disease incidence
cohort data 263
rate of 264
regression equation 264, 265

Dispersion 10, see also Variance

Distribution, see Probability distribution
explanatory variables 116
spread 10
survival times 149, 151

Dose-response study 137, see also Logistic regression, Poisson regression
 ED_{50}, see Median effective dose
Effect graph 188, see also Interaction, graphical interpretation of
Effect modifying factor 270, 271, 278–280, see also Interaction
Epidemiological studies 263–264, see also Cohort, Case-control
Epidemiology 135, 263, 280–281 clinical 280–281
Estimate
approximate asymptotic distribution 82
notation 82, 113
precision 86
Estimated standard deviation 82, 95
Estimated standard error 82
Estimation 54, 84
in 2 × 2 tables 131–135
Examples
abnormal ovulatory cycles and diabetes 164–167
anti-tumor activity in leukemic mice 23–25
assessments of musculoskeletal disease by two physicians 304–306, 306–307
autologous marrow transplants in dogs 25–26
back pain in pregnancy 193–201, 202–204
BILAG scores for systemic lupus erythematosus 300–302, 303
Cardiac Arrhythmia Suppression Trial 235
case-control study of endometrial cancer 268–270, 271–273
cell differentiation and immunooactivation by TNF and IFN 145–148
cohort study of cardiovascular disease 265–268
cohort study of high-risk sexual activity 161–164
cohort study of smoking and coronary deaths 275–280
comparing the return behaviours of whole blood donors 75
coronary artery disease 225–226
diabetes and HLA 202, 204, 205
diagnostic consistency between pathologists 51–53
dose requirement of anesthetic 136–140
efficacy-toxicity study in kidney transplant patients 249–250
γ-interferon in chronic granulomatous disease 235
heights of father-son pairs 112–113
immunological assay 90–109
effect of concentration 100–103
hemophiliacs versus controls 104–109
joint damage in psoriatic arthritis 167–173
leukemic relapse and GVHD 158–159
marrow transplants for aplastic anemia 29–34, 128–129, 130, 131–135
nutritional effects on mouse pups 113–118, 119–120, 122–127
paired enzyme-linked immunosorbent assays (ELISAs) 282–284
PAS and streptomycin for tuberculosis 35–40
physician communication skills 141–142, 144
prenatal care 47–51, 135–136
prothrombin time international normalized ratio (INR) 174–190
randomized clinical trials of prolonged antiplatelet therapy 257–262
return behaviour of whole blood donors 64–66, 75
serum ferritin concentration for iron deficiency anemia 295–296
small-cell lung cancer 233
treating urinary tract infection with enoxacin 26–27
venoocclusive disease of liver 40–42
Wilms’ tumor
chemotherapy 223–225, 228
inadequate radiotherapy/relapse 12–17
study design 228
Expected numbers
  calculating $\kappa$ 305, 306
  in $2 \times 2$ tables 30–31
  in rectangular tables 37, 38
  of deaths in log-rank test 68–69, 71–73
too small 38, 41
Explanations for observed result 16
Explanatory variable 113, 194, see also
  Covariate, Risk factor
  additional information 117, 125
  identification of important 196–200
  joint effects 117, 124–125
Exploratory analysis 193–196
Exposure variable, see Risk factor
  alternative coding for 272–273
Factor 67, 69, 100, 174, 181–183
Failure 19
False discovery rate 206
False negative 209, see also Type II error,
  Diagnostic test
  and surrogate endpoints 235
False positive 209, 240, 247, see also
  Type I error, Diagnostic test
  and surrogate endpoints 235
F distribution 106–110, 124, 179
Fisher's test 19–27
  approximate 28–35
  assumptions 20, 29
  null hypothesis 21
Follow-up 218
Force of mortality 150, see also Hazard
  rate
Frequency 3
Futility index 252
Galton 112
Generalizability studies 303
Generalized estimating equations (GEE) 162, see also Regression model
Global test 124–125, 179, 202, 205, 206, 242
Graphs 194
Hazard rate 150
Health economic measures 242
Heterogeneity 111
Histogram 3–5, 93–94, 101–102
Hypothesis, see Null
generation 201
Incomplete observation 149
Indicator variables, see Categories
Intention to treat, see Clinical trials
Interaction
  and effect modification 271, 278–280
  as a product of indicator variables 183
  as synergistic action in cell
differentiation 146
  between covariates 139, 153, 271–273
effect graph for 188
graphical interpretation of 188
two-factor 181–183
Interval scale 3
Intraclass correlation coefficient (ICC) 300–302
  definition 302
  estimate 302
Kaplan–Meier survival curve 54–66,
  67–68, 149, 251
  computation 62–64
dropping to zero 58
estimating median survival 59
general features 56–61
multiplication of probabilities 58
staircase appearance 58
standard errors 60
undefined 58, 59
Kappa ($\kappa$) coefficient 304–306
  dependence on prevalence 308–309
  for multiple measurement categories 305–306
  for two measurement categories 304–305
  weighted $\kappa$ 306–307
    Cicchetti weights 307
    quadratic weights 307
    relation to ICC 307
Lambda ($\lambda$) 142, 143, 276
  Poisson mean 142, 143, 276
regression model for log $\lambda$ 143, 276
Likelihood ratio statistic 205, 259, 272, 278
Likelihood ratio test 259, 278
Location, measure 8–10
Log-likelihood 205, 272, 273
Log-rank test  67–75, 149, 212, 233
details 68–71
differences designed to detect 67, 70
effectiveness 70
for k groups 71
null hypothesis 67–68
restricted time interval 70
simple example 71–74
stratified 69
test statistic 69
Logistic regression 128–140, 164–167,
196–200, 200–201, 204–205, 257–260,
268–273
conditional analysis 270
for 2 × 2 tables 131–136
for abnormal ovulatory cycles 164–167
for case-control data 268–273
for dose-response data 136–140
for meta-analysis of binary outcome
data 257–260
model 129–130
summary precautions 199–200
with random effects 165, 259
with stratification 133–135, 258, 269
Logistic transform of probability 129
Longitudinal data 160–173, see also
Correlation
Mantel-Haenszel χ² statistic 273–275
Mantel-Haenszel estimate 274
variance 274
Mantel-Haenszel test, see Log-rank test
Maximum likelihood estimation 130, 144
Mean 8–10
estimation 94
population 94, 95
sample 94, 96, 103
value 9
Measurement agreement 303
estimate 303
Measurement repeatability, reproducibility 284
Median 9, 10
sample median survival time 59
Median effective dose 139
confidence interval 139
estimation 139
Meta-analysis 254–262
aim 255
fixed effects versus random effects 259–260
graphical displays 260–262
sensitivity to assumptions 262
study heterogeneity 256–257
qualitative versus quantitative 257
types of data 255–256
Minimization
and randomization in clinical trials 219
as protection against selection bias 219
Model, statistical 111–112
Mu (µ) 9, 10, 94, 95, 96, 97, 98, 101, 103,
104, 105, 109, 231, 247
Multi-factor 111
statistical analysis 1
Multiple comparisons 199, 202–205, 220,
241
Multi-state regression model 167–173
stratified 171–173
Non-randomized studies
possible consequences of 226
Normal data 76, 90–110
checking assumption 91–94, 101–102
comparing means 103–106
independent samples 103–106
with unequal variances 109–110
Normal deviate 83
Normal distribution 5, 76–110
and confidence intervals 84–87
and significance testing 81–84
bell-shaped curve 77
calculation of probabilities 77, 80,
87–89
cumulative probability curve 5, 77, 87
importance 81
mean 77
notation 77
of test statistics 81, 82
probability curve 77–80, 94, 101
standardized 77, 80, 83, 87–89
standardizing transformation 80, 82,
89, 96

Subject Index
use in advanced methodology 81–82, 84–87
variance 77
Normal tables, use 87–89
Normal test statistic 82
critical values 83
Null hypothesis 17, 18, 67, 208, 209
χ² test in a rectangular contingency table 36
comparing means 104–105
Fisher’s test 20–21, 23, 29, 36
log-rank test 67–68
matched pairs binary data 53
paired normal data 101, 103
rejecting 208, 231
when combining 2 × 2 tables 49
Odds ratio 132, see also Case-control study
and relative risk 135
common, see Mantel-Haenszel estimate estimation 132, 135
in a dose-response study 140
in stratified 2 × 2 tables 133, 134
model 268–270
regression equation 268, 269
test for constant 134–135
Ordered variable 196
Orthogonal contrasts, see Clinical trials
Outcome variable 111, 113, 118, 128, 160, 168 see also Response variable
Paired data
binary 46, 51–53
normal 100–103
Panel data 170
Parameter 85
Person-years of follow-up 276
Phi
in active control trials, see (φ)
(Φ(z)) 87, 88
(φ) 236–237
relative efficacy, see (φ)
Poisson distribution 141
deaths due to horsekicks 141
mean 142
Poisson regression 141–148
dose response study 145–148, see also Examples, cell differentiation and
immunostimulation by TNF and IFN
evaluating model fit graphically 148
for cohort studies 145
for death rate 276
for log λ 143
interpreted as relative risk 277
rate ratio 144
relation to logistic regression 145
Population 2, 3, 5, 12, 19, 29, 35, 54, 67, 70, 81, 95, 96, 100, 106, 120
mean 94, 96, 105, see also Mu
variance 94, 95, see also Variance
versus sample 12–13
Power 211, see also Clinical trials
conditional 252
Probability
= area equation 5
calculation 5, 7–8
calculation for 2 × 2 tables 21
right-hand tail 42
success and failure 19–20
Probability curve 5
cumulative 5, 7
Probability density function 5, see also Probability curve
Probability distribution 2–8, see also Statistical tables
χ² 33, 42–45
F 106, 107–108, 124
normal 5, 76–89, 90–110
Poisson 141, 142
t 97–100
test statistic 18, 33
Proportion 19, 145, 211
Proportional hazards 154
testing 157
Proportional hazards regression 149–159, see also Regression model
eexample 152–157, 158–159, 264–268
stratified 155–157, 265
Psi (ψ) 274, 275
p-value 1, 16, 17, 18
Bonferroni adjustment 202, 241
most significant 202
precise 87
Quality-of-life 240, 242
    measures 242
    studies 240

Random effects models 164–167, 237–239
    estimated mean 166–167
    for clustering 239
    for clustering by health professional 239
    for meta-analysis 259–260
    subject-specific parameters 165

Random sample 3

Random variable 2–5
    continuous 3, 5
    discrete 3

Ranking of $2 \times 2$ tables 14

Rate 19

Regression 112–113
    coefficient 113, 131, 143, 151, 153, 162, 163, 169, 170
    equal to 0, see Response variable equation 113
    linear 113
    $Y$ on $X$ versus $X$ on $Y$ 121

Regression model
    Cox 151
    for count data 143, see also Regression model, Poisson
    for log $\lambda$ 143
    for survival data 149
    GEE 162
    Liang-Zeger 161–164
    linear 111–127, 149
    logistic 128–140
    main effects 180
    simplifying a more complex model 182
    marginal 164, 165
    Poisson 141–148, 275–280
    population-averaged 164
    proportional hazards 149–159
    simple linear 114
    subject-specific 165
    testing for additivity 153
    validity 154
    with categorical covariates 174–181
    with subject-specific random effects 165

with two-factor interactions 181–183

Relapse or death, time 149

Relapse rate
    leukemia 158
    population 12–16
    regression equation 158–159
    sample 13

Relative efficacy 236, 245
    experimental treatment to active control 236, 245
    placebo control to standard treatment 236

Relative risk 135, 152–153, see also Poisson regression
    confidence interval 153
    in multi-state models 170
    models 264–268

Relative toxicity
    experimental treatment to control therapy 245

Repeated measurement 160, see also Longitudinal data

Response variable 113, 114, 118, 143, 194
    regression coefficient equal to 0 116

Risk factor 263
    relation to disease incidence 263

Robustness 91

Row totals 20
    fixed and random 34

$s^2$, variance estimate 95
    pooled estimate 104

Sample 3, 13

Sample size
    calculations 207–216
    examples 211–214
    general aspects 207–211
    inadequate 207
    using software packages 211

Sampling uncertainty 16, 17, 18

Sequential analysis 230–233, 244–250
    stopping criterion 231

Sigma
    $\Sigma$ 3
    $(\sigma)$ 10

Significance 1

Significance level 12, 16, 17, 18, see also $p$-value
discounting 201
exact 28
in efficacy-toxicity trials 247
small 16
Significance tests 11–18
common features 17–18
one-sided 245–246
repeated 228–230
Standard deviation 10, see also
Standard error
sample 95
Standard error 60, 82
Standardized mortality ratio 145
Statistical calculations, formalism 191, 200
Statistical tables 8, 21
\(\chi^2\) distribution 44
F distribution 107–108
normal distribution 83, 88
t distribution 99
Stochastic curtailment, see Clinical trials
Stratification 46, 48, 69, 100, 111, 133
treatment assignment 218–219
Subscripted letters 2
Success 19
factors influencing probability 47
Sum of squares, see Analysis of variance
Summary response, see Design of clinical trials
Surrogate endpoints/markers 234–236
definition of 235
hazards of using 235
Survival curve 54, 151, see also
Kaplan-Meier
Survival data, see Kaplan-Meier,
Proportional hazards regression characteristics 149
Survival function 54, 151
Systematic review, see Meta-analysis
t distribution 97–99
t test, see Comparisons with normal data
paired 100–103
single-sample 97–100	wo-sample 103–106
Tables, see Contingency, Statistical tables
Tabulation 193, 194, 195
Test of significance 11–18, see also
Significance tests
Test statistic 18
\(\chi^2\) test in 2 \times 2 table 31–32
\(\chi^2\) test in rectangular table 39
comparing log–likelihoods 205
comparing means 104
comparing variances 106
F test in ANOVA tables 124, 125, 126
Fisher’s test 21
paired binary data 52–53
paired normal data 101
testing mean of normal data 98
testing regression coefficients equal to zero 116, 130, 143
Transforming data 94, 101, 161
Treatment comparison 196, 226
overestimates of difference 225
Type I error 209, 240
false positive 209, 240
in selection procedures 244
Type II error 209
false negative 209
Variable, see Random
dependent 113, see also Response variable
explanatory 113, 114, 116, 117, 143, 146, 194, see also Covariate
independent 113
outcome, see Outcome variable
Variance 10
estimation 95, 104
testing for equality 106–110
Wilcoxon test 70
Within patient comparisons 187
\(x\), sample mean 94, 95
Yates’ continuity correction 32
Youden 81
Z statistic 84